業績

2024

Hamaguchi-Suzuki N, Adachi N, Moriya T, Yasuda S, Kawasaki M, Suzuki K, Ogasawara S, Anzai N, Senda T, Murata T. Cryo-EM structure of P-glycoprotein bound to triple elacridar inhibitor molecules. Biochem Biophys Res Commun., 709:149855, 2024.

Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Cancer Sci., 115(3):937-953, 2024.

Sakamoto S, Ando K, Pae S, Zhao X, Sakai K, Sato K, Saito S, Yamada Y, Rii J, Goto Y, Sazuka T, Imamura Y, Anzai N, Akakura K, Nishio K, Ichikawa T. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer. Anticancer Res., 44(2):639-647, 2024.

Soejima Y, Yoshioka H, Guro S, Sato H, Hatakeyama H, Sato Y, Fujimoto Y, Anzai N, Hisaka A. Exercise training outcomes in patients with chronic heart failure with reduced ejection fraction depend on patient background. Front Cardiovasc Med., 11:1330235, 2024.

2023

Saito S, Hashimoto H, Wakashin H, Ishibane M, Pae S, Saito S, Reien Y, Hirayama Y, Seo Y, Mizushima T, Anzai N. Central administered xenin induced Fos expression in nesfatin-1 neurons in rats. Brain Res Bull., 110788, 2023.

Jinakote M, Jutabha P, Anzai N, Ontawong A, Soodvilai S, Inchai J, Vaddhanaphuti CS. Interaction of buspirone and its major metabolites with human organic cation transporters. Fundam Clin Pharmacol., 37(4):833-842, 2023.

Zhao X, Sakamoto S, Wei J, Pae S, Saito S, Sazuka T, Imamura Y, Anzai N, Ichikawa T. Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer. Int J Mol Sci., 24(7):6178, 2023.

Otani N, Ouchi M, Mizuta E, Morita A, Fujita T, Anzai N, Hisatome I. Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia. Biomedicines, 11(5):1255, 2023.

Saito S, Sakamoto S, Higuchi K, Sato K, Zhao X, Wakai K, Kanesaka M, Kamada S, Takeuchi N, Sazuka T, Imamura Y, Anzai N, Ichikawa T, Kawakami E. Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy. Sci Rep., 13(1):6325, 2023.

2022

Pae S, Sakamoto S, Zhao X, Saito S, Tamura T, Imamura Y, Sazuka T, Reien Y, Hirayama Y, Hashimoto H, Kanai Y, Ichikawa T, Anzai N. Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective. J Pharmacol Sci., 150(4):251-258, 2022.

Ishibane M, Hashimoto H, Kaneko M, Saito S, Pae S, Saito S, Reien Y, Hirayama Y, Higashi-Kuwata N, Mitsuya H, Anzai N. Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters. ​​​​J Pharmacol Sci., 150(4):201-203, 2022.

Akiyama M, Unoki T, Aoki H, Nishimura A, Shinkai Y, Warabi E, Nishiyama K, Furumoto Y, Anzai N, Akaike T, Nishida M, Kumagai Y. Cystine-dependent antiporters buffer against excess intracellular reactive sulfur species-induced stress. Redox Biol., 17;57:102514, 2022.

Owada T, Kurasawa K, Endou H, Fujita T, Anzai N, Hayashi K. LAT1-specific inhibitor ameliorates severe autoimmune arthritis in SKG mouse. Int Immunopharmacol., 109:108817, 2022.

Hirayama Y, Anzai N, Kinouchi H, Koizumi S. P2X7 Receptors in Astrocytes: A Switch for Ischemic Tolerance. Molecules, 27(12):3655, 2022.

Ouchi M, Morita A, Satoh K, Kobayashi S, Terada M, Kon H, Hayashi K, Suzuki T, Oba K, Sugihara H, Yasutake M, Anzai N, Fujita T. Effects of 1,5-anhydro-D-glucitol on insulin secretion both in in vitro and ex vivo pancreatic preparations. J Pharmacol Sci., 149(2):66-72, 2022.

Otani N, Ouchi M, Misawa K, Hisatome I, Anzai N. Hypouricemia and Urate Transporters. Biomedicines, 10(3):652, 2022.

Zhao X, Sakamoto S, Maimaiti M, Anzai N, Ichikawa T. Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways. Cancers (Basel), 14(1):229, 2022.

Hayashi K, Anzai N. L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy. J Pharmacol Sci., 148(1):31-40, 2022.

2021

Morita A, Ouchi M, Satoh K, Kobayashi S, Terada M, Wakashin H, Kon H, Hayashi K, Anzai N, Shimizu A, Sugihara H, Oba K, Fujita T. The Effects of Trypsin Inhibitor on Insulin Secretion Using Rat Pancreas in an Organ Bath. In Vivo, 35(5):2551-2558, 2021.

Betsunoh H, Sakamoto S, Kaji Y, Nukui A, Kobayashi M, Yashi M, Hayashi K, Anzai N, Kamai T. Clinical Significance of 18F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma. Anticancer Res., 41(10):5179-5188, 2021.

Hirayama Y, Anzai N, Koizumi S. Mechanisms underlying sensitization of P2X7 receptors in astrocytes for induction of ischemic tolerance. Glia, 69(9):2100-2110, 2021.

Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Tomohiko I. Functional analysis of LAT3 in prostate cancer: its downstream target and relationship with androgen receptor. Cancer Sci., 112(9):3871-3883, 2021.

Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2. Sci Rep., 11(1):11478, 2021.

Kaneko M, Reien Y, Morio H, Fukuuchi T, Kaneko K, Hirayama Y, Hashimoto H, Kuwata N, Mitsuya H, Anzai N. Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters. J Pharmacol Sci., 146(2):82-87, 2021.

Morio H, Reien Y, Hirayama Y, Hashimoto H, Anzai N. Protein kinase C activation upregulates human L-type amino acid transporter 2 function. J Physiol Sci., 71(1):11, 2021.

Ando K, Sakamoto S, Saito S, Maimaiti M, Imamura Y, Sazuka T, Sato N, Komiya A, Anzai N, Ichikawa T. Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers, 13(4):773, 2021.

Sato M, Harada-Shoji N, Toyohara T, Soga T, Itoh M, Miyashita M, Tada H, Amari M, Anzai N, Furumoto S, Abe T, Suzuki T, Ishida T, Sasano H. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
Sci Rep., 11(1):589, 2021.

Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara KI, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M, Imamura Y, Furihata T, Sakamoto S, Komiya A, Anzai N, Kanai Y, Luo J, Ichikawa T, Kaneda A. Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl Oncol., 14(1):100915, 2021.

2020

Okunushi K, Furihata T, Morio H, Muto Y, Higuchi K, Kaneko M, Otsuka Y, Ohno Y, Watanabe Y, Reien Y, Nakagawa K, Sakamoto S, Wakashin H, Shimojo N, Anzai N. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function. J Pharmacol Sci., 144(1):16-22, 2020.

Hisaka A, Yoshioka H, Hatakeyama H, Sato H, Onouchi Y, Anzai N. Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World.J Clin Med., 9(6):E1904, 2020.

Mishima E, Anzai N, Miyazaki M, Abe T. Uric Acid Elevation by Favipiravir, an Antiviral Drug. Tohoku J Exp Med., 251(2):87-90, 2020.

Otani N, Ouchi M, Kudo H, Tsuruoka S, Hisatome I, Anzai N. Recent approaches to gout drug discovery: an update. Expert Opin Drug Discov., 1-12, 2020.

Gottier Nwafor J, Nowik M, Anzai N, Endou H, Wagner CA. Metabolic Acidosis Alters Expression of Slc22 Transporters in Mouse Kidney.Kidney Blood Press Res., 45(2):263-274, 2020.

Misawa K, Hasegawa T, Mishima E, Jutabha P, Ouchi M, Kojima K, Kawai Y, Matsuo M, Anzai N, Nagasaki M. Contribution of Rare Variants of the SLC22A12 Gene to the Missing Heritability of Serum Urate Levels.Genetics, 214(4):1079-1090, 2020.

Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Sci Rep., 10(1):1292, 2020.

Hayashi K, Nakazato Y, Morito N, Sagi M, Fujita T, Anzai N, Chida M. Fluvastatin is effective against thymic carcinoma. Life Sci., 240:117110, 2020.

Morita A, Ouchi M, Satoh K, Terada M, Kon H, Wakashin H, Hayashi K, Anzai N, Oba K, Shimizu A, Fujita T. Development of an organ bath technique for isolated rat pancreas preparations to assess the effect of 1,5-AG on insulin secretion. Exp Anim., 69(2):127-134, 2020.

Hayashi K, Kaminuma O, Nishimura T, Saeki M, Matsuoka K, Hiroi T, Jutabha P, Iwata Y, Sugiura K, Owada T, Kurasawa K, Okayasu I, Ouchi M, Fujita T, Kanai Y, Endou H, Anzai N. LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation. Allergy, 75(2):463-467, 2020.

2019

Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, Matsushima J, Furihata T, Ikehara Y, Ichikawa T, Anzai N. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci Rep., 9(1):16776, 2019.

Ito R, Umehara K, Suzuki S, Kitamura K, Nunoya KI, Yamaura Y, Imawaka H, Izumi S, Wakayama N, Komori T, Anzai N, Akita H, Furihata T. A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies. Mol Pharm., 16(11):4461-4471, 2019.

Otsuka Y, Furihata T, Nakagawa K, Ohno Y, Reien Y, Ouchi M, Wakashin H, Tsuruoka S, Anzai N. Sodium-coupled monocarboxylate transporter 1 interacts with the RING finger- and PDZ domain-containing protein PDZRN3. J Physiol Sci., 69(4):635-642, 2019.

Srivastava S, Nakagawa K, He X, Kimura T, Fukutomi T, Miyauchi S, Sakurai H, Anzai N. Identification of the multivalent PDZ protein PDZK1 as a binding partner of sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8) and SMCT2 (SLC5A12). J Physiol Sci., 69(2):399-408, 2019.

Muto Y, Furihata T, Kaneko M, Higuchi K, Okunushi K, Morio H, Reien Y, Uesato M, Matsubara H, Anzai N. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203. Anticancer Res., 39(1):159-165, 2019.

2018

Ohe T, Umezawa R, Kitagawara Y, Yasuda D, Takahashi K, Nakamura S, Abe A, Sekine S, Ito K, Okunushi K, Morio H, Furihata T, Anzai N, Mashino T. Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation. Bioorg Med Chem Lett., 28(23-24):3708-3711, 2018.

Otani N, Toyoda S, Sakuma M, Hayashi K, Ouchi M, Fujita T, Anzai N, Tanaka A, Node K, Uemura N, Inoue T. Effects of uric acid on vascular endothelial function from bedside to bench. Hypertens Res., 41(11):923-931, 2018.

Kitamura K, Ito R, Umehara K, Morio H, Saito K, Suzuki S, Hashimoto M, Saito Y, Anzai N, Akita H, Chiba K, Furihata T. Differentiated HASTR/ci35 cells: A promising in vitro human astrocyte model for facilitating CNS drug development studies. J Pharmacol Sci., 137(4):350-358, 2018.

Shimizu T, Takayanagi K, Iwashita T, Ikari A, Anzai N, Okazaki S, Hara H, Hatano M, Sano T, Ogawa T, Kanozawa K, Hasegawa H. Down-regulation of magnesium transporting molecule, claudin-16, as a possible cause of hypermagnesiuria with the development of tubulo-interstitial nephropathy. Magnes Res., 31(1):11-23, 2018.

Sun Y, Piñón Hofbauer J, Harada M, Wöss K, Koller U, Morio H, Stierschneider A, Kitamura K, Hashimoto M, Chiba K, Akita H, Anzai N, Reichelt J, Bauer JW, Guttmann-Gruber C, Furihata T. Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technology. Cancer Lett., 433:107-116, 2018.

Hori T, Ouchi M, Otani N, Nohara M, Morita A, Otsuka Y, Jutabha P, Shibasaki I, Matsushita Y, Fujita T, Fukuda H, Anzai N. The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate under-excretion animal models. J Pharmacol Sci., 136(4):196-202, 2018.

Harada S, Kajihara R, Muramoto R, Jutabha P, Anzai N, Nemoto T. Catalytic asymmetric synthesis of α-methyl-p-boronophenylalanine. Bioorg Med Chem Lett., 28(10):1915-1918, 2018.

Morio H, Sun Y, Harada M, Ide H, Shimozato O, Zhou X, Higashi K, Yuki R, Yamaguchi N, Hofbauer JP, Guttmann-Gruber C, Anzai N, Akita H, Chiba K, Furihata T. Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker. Biol Pharm Bull., 41(3):445-449, 2018.

Zhu M, Koibuchi A, Ide H, Morio H, Shibuya M, Kamiichi A, Tsubota A, Anzai N, Akita H, Chiba K, Furihata T. Development of a New Conditionally Immortalized Human Liver Sinusoidal Endothelial Cells. Biol Pharm Bull., 41(3):440-444, 2018.

Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol., 315(2):F386-F394, 2018.

Ouchi M, Oba K, Kaku K, Suganami H, Yoshida A, Fukunaka Y, Jutabha P, Morita A, Otani N, Hayashi K, Fujita T, Suzuki T, Yasutake M, Anzai N. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes Obes Metab., 20(4):1061-1065, 2018.

Umehara K, Sun Y, Hiura S, Hamada K, Itoh M, Kitamura K, Oshima M, Iwama A, Saito K, Anzai N, Chiba K, Akita H, Furihata T. A New Conditionally Immortalized Human Fetal Brain Pericyte Cell Line: Establishment and Functional Characterization as a Promising Tool for Human Brain Pericyte Studies. Mol Neurobiol., 55(7):5993-6006, 2018.

Morita A, Ouchi M, Terada M, Kon H, Kishimoto S, Satoh K, Otani N, Hayashi K, Fujita T, Inoue KI, Anzai N. Reproducible insulin secretion from isolated rat pancreas preparations using an organ bath. Exp Anim., 67(1):15-22, 2018.

2017

Ohno Y, Otsuka Y, Nohara M, Furihata T, Kuse Y, Itoh Y, Hara H, Anzai N. Characterization of an L-Carnitine Transport System in Murine Photoreceptor Cell Line. Biol Pharm Bull., 40(12):2110-2116, 2017.

Watanabe Y, Matsumoto A, Miki T, Seino S, Anzai N, Nakaya H. Electrophysiological analyses of transgenic mice overexpressing KCNJ8 with S422L mutation in cardiomyocytes. J Pharmacol Sci., 135(1):37-43, 2017.

Furihata T, Anzai N. Functional Expression of Organic Ion Transporters in Astrocytes and Their Potential as a Drug Target in the Treatment of Central Nervous System Diseases. Biol Pharm Bull., 40(8):1153-1160, 2017.

Marunaka K, Furukawa C, Fujii N, Kimura T, Furuta T, Matsunaga T, Endo S, Hasegawa H, Anzai N, Yamazaki Y, Yamaguchi M, Ikari A. The RING finger- and PDZ domain-containing protein PDZRN3 controls localization of the Mg2+ regulator claudin-16 in renal tube epithelial cells. J Biol Chem., 292(31):13034-13044, 2017.

Sun Y, Harada M, Shimozato O, Souda H, Takiguchi N, Nabeya Y, Kamijo T, Akita H, Anzai N, Chiba K, Furihata T. Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer. Biomark Med., 11(8):629-639, 2017.

Yothaisong S, Dokduang H, Anzai N, Hayashi K, Namwat N, Yongvanit P, Sangkhamanon S, Jutabha P, Endou H, Loilome W. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol., 39(3):1010428317694545, 2017.

Hayashi K, Anzai N. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol., 9(1):21-29, 2017.

Furihata T, Morio H, Zhu M, Suzuki Y, Ide H, Tsubota A, Fu Z, Anzai N, Chiba K. Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet., 32(1):116-119, 2017.

Shimizu Y, Satou M, Hayashi K, Nakamura Y, Fujimaki M, Horibata Y, Ando H, Watanabe T, Shiobara T, Chibana K, Takemasa A, Sugimoto H, Anzai N, Ishii Y. Matrix-assisted laser desorption/ionization imaging mass spectrometry reveals changes of phospholipid distribution in induced pluripotent stem cell colony differentiation. Anal Bioanal Chem., 409(4):1007-1016, 2017.

Otani N, Ouchi M, Hayashi K, Jutabha P, Anzai N. Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. Anat Sci Int., 92(2):200-206, 2017.

Yothaisong S, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A, Jutabha P, Anzai N, Tassaneeyakul W, Tangsucharit P, Loilome W. Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. Parasitol Int., 66(4):471-478, 2017.

2016

Kokura K, Kuromi Y, Endo T, Anzai N, Kazuki Y, Oshimura M, Ohbayashi T. A kidney injury molecule-1 (Kim-1) gene reporter in a mouse artificial chromosome: the responsiveness to cisplatin toxicity in immortalized mouse kidney S3 cells. J Gene Med., 18(10):273-281, 2016.

Sakoh T, Nakayama M, Tsuchihashi T, Yoshitomi R, Tanaka S, Katafuchi E, Fukui A, Shikuwa Y, Anzai N, Kitazono T, Tsuruya K. Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease. Metabolism, 65(10):1498-507, 2016.

Hayashi K, Jutabha P, Maeda S, Supak Y, Ouchi M, Endou H, Fujita T, Chida M, Anzai N. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells. J Pharmacol Sci., 132(3):201-204, 2016.

Breljak D, Ljubojević M, Hagos Y, Micek V, Balen Eror D, Vrhovac Madunić I, Brzica H, Karaica D, Radović N, Kraus O, Anzai N, Koepsell H, Burckhardt G, Burckhardt BC, Sabolić I. Distribution of organic anion transporters NaDC3 and OAT1-3 along the human nephron. Am J Physiol Renal Physiol., 311(1):F227-38, 2016.

Hayashi K, Ouchi M, Endou H, Anzai N. HOXB9 acts as a negative regulator of activated human T cells in response to amino acid deficiency. Immunol Cell Biol., 94(6):612-7, 2016.

Jaiyen C, Jutabha P, Anzai N, Lungkaphin A, Soodvilai S, Srimaroeng C. Interaction of green tea catechins with renal organic cation transporter 2. Xenobiotica, 46(7):641-650, 2016.

Ljubojević M, Breljak D, Herak-Kramberger CM, Anzai N, Sabolić I. Expression of basolateral organic anion and cation transporters in experimental cadmium nephrotoxicity in rat kidney. Arch Toxicol., 90(3):525-41, 2016.

2008 (Selected publication)

Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem., 283(40):26834-8, 2008.